Table 2.
QTL | Trait | Trial | n | Sig. threshold | Genetic marker | Chr | Peak Position (Mb) | –log10(P) | Alt. allele effect | Var. (%) |
---|---|---|---|---|---|---|---|---|---|---|
QFt.niab-2B.1 | Ft | Core19 | 596 | 4.86 | AX.94970315 | 2B | 26.6 | 6.34 | − 0.96 | 0.84 |
QFt.niab-2B.1 | Ft | Full21 | 2389 | 4.97 | AX.95082190 | 2B | 58.1 | 6.25 | − 0.99 | 1.10 |
QFt.niab-2D.1 | Ft | Core19 | 596 | 4.86 | AX.94779177 | 2D | 14.9 | 5.33 | − 0.86 | 0.04 |
QFt.niab-2D.1 | Ft | Core21 | 277 | 4.66 | AX.94603120 | 2D | 33.4 | 10.74 | − 1.77 | 10.75 |
QFt.niab-4A.1 | Ft | Core18 | 852 | 4.66 | AX.94552332 | 4A | 735.8 | 10.09 | − 0.68 | 0.18 |
QFt.niab-4A.1 | Ft | Full21 | 2389 | 4.97 | AX.95165912 | 4A | 681.4 | 10.31 | − 0.84 | 0.86 |
QFt.niab-7D.1 | Ft | Core18 | 852 | 4.66 | AX.95229555 | 7D | 17.8 | 8.50 | − 0.62 | 0.03 |
QFt.niab-7D.1 | Ft | Core20 | 457 | 4.66 | AX.94929727 | 7D | 61.2 | 5.87 | − 1.06 | 5.07 |
QFt.niab-7D.1 | Ft | Full21 | 2389 | 4.97 | AX.94688897 | 7D | 32.0 | 5.33 | − 0.59 | < 0.01 |
QPh.niab-5A.2 | Ph | Core18 | 852 | 4.66 | AX.94462177 | 5A | 527.9 | 8.52 | 2.25 | 0.34 |
QPh.niab-5A.2 | Ph | Full21 | 2389 | 4.97 | AX.94462177 | 5A | 527.9 | 5.36 | 1.50 | 1.07 |
QPh.niab-6A.1 | Ph | Core17 | 253 | 4.46 | AX.94474129 | 6A | 114.2 | 6.18 | 3.61 | 0.87 |
QPh.niab-6A.1 | Ph | Core18 | 852 | 4.66 | AX.95630086 | 6A | 230.7 | 12.63 | 3.18 | 3.28 |
QPh.niab-6A.1 | Ph | Core21 | 277 | 4.66 | AX.95630086 | 6A | 230.7 | 6.73 | 4.25 | 9.81 |
QPh.niab-6A.1 | Ph | Full21 | 2389 | 4.97 | AX.95159326 | 6A | 405.4 | 19.10 | 3.06 | 2.45 |
QPh.niab-6D.1 | Ph | Core17 | 253 | 4.46 | AX.94940605 | 6D | 84.3 | 6.06 | 3.43 | 0.99 |
QPh.niab-6D.1 | Ph | Core18 | 852 | 4.66 | AX.94940605 | 6D | 84.3 | 6.71 | 2.01 | < 0.01 |
QPh.niab-6D.1 | Ph | Full21 | 2389 | 4.97 | AX.94940605 | 6D | 84.3 | 6.64 | 1.58 | < 0.01 |
QYr.niab-4D.1 | Yr | Core17 | 253 | 4.46 | AX.94546744 | 4D | 1.4 | 4.90 | − 2.25 | 7.89 |
QYr.niab-4D.1 | Yr | Core18 | 852 | 4.66 | AX.94546744 | 4D | 1.4 | 14.27 | − 3.93 | 7.76 |
QYr.niab-4D.1 | Yr | Full21 | 2389 | 4.97 | AX.94546744 | 4D | 1.4 | 13.82 | − 0.78 | 2.98 |
The chromosome (Chr.) and physical position (measured in Mb) for each peak marker of each QTL are listed. ‘−log10(P)’ represents the −log10(P-value) for each QTL; ‘Var.’ shows percentage variation explained by each QTL. Significance thresholds (Sig. threshold) were estimated with a Bonferroni-type correction that uses effective markers based on linkage disequilibrium for a corrected P = 0.05. The ‘Alt. allele effect’ represents the dosage of the alternative SHW allele (where ‘Robigus’ was the reference) and ‘n’ was the number of genotypes used in the genetic mapping for each trial